NeuBase Therapeutics, Inc.
At Close: 4:00 PM
NBSE Stock Price Graph
NBSE Stock Price Today
NeuBase Therapeutics, Inc. (NBSE) stock rallied over 1.32% intraday to trade at $0.689 a share on NASDAQ. The stock opened with a loss of -0.12% at $0.65 and touched an intraday high of $0.65, rising 6.00% against the last close of $0.65. The NeuBase Therapeutics, Inc. in stock market went to a low of $0.60 during the session.
NBSE Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
NBSE Stock Price History Chart
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Frequently Asked Questions
What is the current NeuBase Therapeutics, Inc. (NBSE) stock price?
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) stock price is $0.69 in the last trading session. During the trading session, NBSE stock reached the peak price of $0.65 while $0.60 was the lowest point it dropped to. The percentage change in NBSE stock occurred in the recent session was 1.32% while the dollar amount for the price change in NBSE stock was $0.01.
NBSE's industry and sector of operation?
The NASDAQ listed NBSE is part of Biotechnology industry that operates in the broader Healthcare sector. NeuBase Therapeutics, Inc. , a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
Who are the executives of NBSE?
Mr. Todd P. Branning
Chief Financial Officer & Sec.
Dr. Ron Sarkar M.B.A., Ph.D.
Senior Vice President of Corporation Strategy & Bus. Devel.
Dr. Dietrich A. Stephan Ph.D.
Founder, Chief Executive Officer & Director
Dr. Robert J. Zamboni Ph.D.
Chief of Preclinical Devel. & Member of Scientific Advisory Board
How NBSE did perform over past 52-week?
NBSE's closing price is 0.45% higher than its 52-week low of $0.6 where as its distance from 52-week high of $8.2 is -0.88%.
How many employees does NBSE have?
Number of NBSE employees currently stands at 37.00. NBSE operates from 350 Technology Drive, Pittsburgh, PA 15219, US.
Link for NBSE official website?
Official Website of NBSE is: https://www.neubasetherapeutics.com
How do I contact NBSE?
How many shares of NBSE are traded daily?
NBSE stock volume for the day was 15471.00 shares. The average number of NBSE shares traded daily for last 3 months was 2.21 Million.
What is the market cap of NBSE currently?
The market value of NBSE currently stands at $2.57 Million with its latest stock price at $0.69 and 3.73 Million of its shares outstanding.